POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

Percentage of Participants With Rapid Virological Response at Week 4

Rapid Virological Response (RVR) is defined as participants with) undetectable HCV RNA at 4 weeks after initiation of the treatment period. The detection limit of HCV RNA was 15 IU/mL by qualitative PCR.

Time frame: At Week 4

Percentage of Participants With Virological Response at Week 24

Virological response is defined as participants with undetectable HCV RNA after the last dose of study drug (Week 24).

Time frame: At Week 24

Percentage of Participants With Virological Relapse

Virological relapse is defined as participants with virological response (undetectable HCV RNA) but did not achieve SVR.

Time frame: At week 48

Percentage of Participants With Positive Predictive Value

Positive predictive value is defined as participants with RVR who did not achieve SVR.

Time frame: At Week 48

Number of Participants With Any Adverse Events and Any Serious Adverse Events

An any adverse events (AEs) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An serious adverse events (SAEs) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.

Time frame: Up to 48 weeks

Mean Percent Change From Baseline in Hematology Parameters at Weeks 2, 4, 12, 24, and 48

Hematology parameters included hemoglobin, hematocrit, leukocytes, neutrophils and platelets.

Time frame: At Baseline (Day 0), Week 2, Week 4, Week 12, Week 24 and Week 48

Mean Percent Change From Baseline in Biochemistry Parameters at Weeks 4, 12, 24 and 48

Biochemistry parameters included alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyl transpeptidase (Gamma-GT),fasting cholesterol, blood glucose, insulin, total bilirubin, creatinine, triglycerides, homeostatic model assessment score, prothrombin time (PT) and international normalized ratio (INR). The homeostatic model assessment (HOMA) score is a method used to quantify insulin resistance. HOMA score = (fasting glucose in mg/dL × fasting insulin in μIU/mL) / 405. A normal participant can have a HOMA score up to 3. A patient with a score of \>3 is definitely insulin resistance. Low HOMA score indicate high insulin resistance, whereas high HOMA score indicate low insulin resistance.

Time frame: Baseline, Week 4, Week 12, Week 24 and Week 48